The molecular mechanisms of TRAIL resistance in cancer cells: Help in designing new drugs

Current Pharmaceutical Design

Volumn 20, Issue 42, 2014, Pages 6714-6722

  Wang, Feng ^a,b   Lin, Junsheng ^a   Xu, Ruian ^a  

^a HUAQIAO UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

AKt; Cancer; Death receptor; Lipid raft; Molecular mechanism; NF B; Resistance; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; DEATH RECEPTOR 4; DEATH RECEPTOR 5; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEW DRUG; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; TNFSF10 PROTEIN, HUMAN;

ARTICLE; CANCER CELL LINE; CANCER RESISTANCE; CELL MEMBRANE; DRUG DESIGN; OUTCOME ASSESSMENT; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; APOPTOSIS; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; METABOLISM; NEOPLASMS; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

APOPTOSIS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84911472841     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140929100735     Document Type: Article

References (116)

1. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apopto-sis. Immunity 1995; 3: 673-82.
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-90.
3. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-63.
4. Shi J, Zheng D, Liu Y, et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005; 65: 1687-92.
5. Soria JC, Smit E, Khayat D, et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with pacli-taxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2010; 28: 1527-33.
6. von Pawel J, Harvey JH, Spigel DR, et al. Phase II trial of ma-patumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2014; 15: 188-196 e2.
7. Greco FA, Bonomi P, Crawford J, et al. Phase 2 study of mapatu-mumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008; 61: 82-90.
8. Forero-Torres A, Shah J, Wood T, et al. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 2010; 25: 13-9.
9. Forero-Torres A, Infante JR, Waterhouse D, et al. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer. Cancer Med 2013; 2: 925-32.
10. Trarbach T, Moehler M, Heinemann V, et al. Phase II trial of ma-patumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 2010; 102: 506-12.
11. Wainberg ZA, Messersmith WA, Peddi PF, et al. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2013; 12: 248-54.
12. Mom CH, Verweij J, Oldenhuis CN, et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 2009; 15: 5584-90.
13. Leong S, Cohen RB, Gustafson DL, et al. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and car-boplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 2009; 27: 4413-21.
14. Sharma S, de Vries EG, Infante JR, et al. Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs 2014; 32: 135-44.
15. Dyer MJ, MacFarlane M, Cohen GM. Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol 2007; 25: 4505-6.
16. Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist Updat 2010; 13: 2-15.
17. Bosman MC, Reis CR, Schuringa JJ, Vellenga E, Quax WJ. Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to os-teoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment. J Biol Chem 2014; 289: 1071-8.
18. Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003; 9: 3397-405.
19. Arts HJ, de Jong S, Hollema H, ten Hoor K, van der Zee AG, de Vries EG. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol Oncol 2004; 92: 794-800.
20. Pettersen I, Bakkelund W, Smedsrod B, Sveinbjornsson B. Osteo-protegerin is expressed in colon carcinoma cells. Anticancer Res 2005; 25: 3809-16.
21. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002; 62: 1619-23.
22. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 2005; 11: 5188-94.
23. Van Poznak C, Cross SS, Saggese M, et al. Expression of osteopro-tegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol 2006; 59: 56-63.
24. Younes M, Georgakis GV, Rahmani M, Beer D, Younes A. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma. Eur J Cancer 2006; 42: 542-7.
25. Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 2005; 5: 54.
26. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 2007; 6: 2103-12.
27. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26: 3621-30.
28. Cooper WA, Kohonen-Corish MR, Zhuang L, et al. Role and prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand death receptor DR5 in nonsmall-cell lung cancer and precursor lesions. Cancer 2008; 113: 135-42.
29. Zhuang L, Lee CS, Scolyer RA, et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum Pathol 2006; 37: 1286-94.
30. Maduro JH, Noordhuis MG, ten Hoor KA, et al. The prognostic value of TRAIL and its death receptors in cervical cancer. Int J Ra-diat Oncol Biol Phys 2009; 75: 203-11.
31. Ganten TM, Sykora J, Koschny R, et al. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J Mol Med (Berl) 2009; 87: 995-1007.
32. Ouellet V, Le Page C, Madore J, et al. An apoptotic molecular network identified by microarray: on the TRAIL to new insights in epithelial ovarian cancer. Cancer 2007; 110: 297-308.
33. Leithner K, Stacher E, Wurm R, et al. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy. Lung Cancer 2009; 65: 98-104.
34. Song JJ, Szczepanski MJ, Kim SY, et al. c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance. Cell Signal 2010; 22: 553-63.
35. Schmidt MHH, Furnari FB, Cavenee WK, Bogler O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci USA 2003; 100: 6505-6510.
36. Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev 2009; 35: 280-8.
37. Chen SZ, Fu L, Raja SM, Yue P, Khuri FR, Sun SY. Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of Geranylgeranyl-transferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. Molecular Cancer 2010; 9: 23.
38. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599-609.
39. Ichikawa K, Liu WM, Zhao LM, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954-960.
40. Shi J, Liu YX, Zheng Y, et al. Therapeutic expression of an antideath receptor 5 single-chain fixed-variable region prevents tumor growth in mice. Cancer Res 2006; 66: 11946-11953.
41. Leverkus M, Sprick MR, Wachter T, et al. TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2. J Invest Dermatol 2003; 121: 149-55.
42. Reis CR, van der Sloot AM, Natoni A, et al. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homo-trimerizing TRAIL variants. Cell Death Dis 2010; 1: e83.
43. Wajant H, Moosmayer D, Wuest T, et al. Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001; 20: 4101-4106.
44. Vigneswaran N, Baucum DC, Wu J, et al. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression. BMC Cancer 2007; 7: 108.
45. Duiker EW, van der Zee AGJ, de Graeff P, et al. The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol 2010; 116: 549-555.
46. Tarragona J, Llecha N, Santacana M, et al. DcR1 expression in endometrial carcinomas. Virchows Arch 2010; 456: 39-44.
47. Sanlioglu AD, Dirice E, Elpek O, et al. High TRAIL Death Receptor 4 and Decoy Receptor 2 Expression Correlates With Significant Cell Death in Pancreatic Ductal Adenocarcinoma Patients. Pancreas 2009; 38: 154-160.
48. Aydin C, Sanlioglu AD, Karacay B, et al. Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells. Hum Gene Ther 2007; 18: 39-50.
49. Buneker C, Mohr A, Zwacka RM. The TRAIL-receptor-1: TRAIL-receptor-3 and-4 ratio is a predictor for TRAIL sensitivity of cancer cells. Oncol Rep 2009; 21: 1289-95.
50. Pei GT, Wu CW, Lin WW. Hypoxia-induced decoy receptor 2 gene expression is regulated via a hypoxia-inducible factor 1 alpha-mediated mechanism. Biochem Biophys Res Commun 2010; 391: 1274-1279.
51. Clancy L, Mruk K, Archer K, et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 2005; 102: 18099-18104.
52. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006; 26: 7046-7055.
53. Lalaoui N, Morle A, Merino D, et al. TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT. PLoS One 2011; 6: e19679.
54. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science 2010; 327: 46-50.
55. Simons K, Vaz WLC. Model systems, lipid rafts, and cell membranes. Annual Review of Biophysics and Biomolecular Structure 2004; 33: 269-295.
56. Song JH, Tse MCL, Bellail A, et al. Lipid rafts and nonrafts mediate tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic and nonapoptotic signals in non-small cell lung carcinoma cells. Cancer Res 2007; 67: 6946-6955.
57. Marconi M, Ascione B, Ciarlo L, et al. Constitutive localization of DR4 in lipid rafts is mandatory for TRAIL-induced apoptosis in B-cell hematologic malignancies. Cell Death Dis 2013; 4: e863.
58. Ouyang W, Yang CX, Liu Y, et al. Redistribution of DR4 and DR5 in lipid rafts accounts for the sensitivity to TRAIL in NSCLC cells. Int J Oncol 2011; 39: 1577-1586.
59. Linderoth E, Pilia G, Mahajan NP, Ferby I. Activated Cdc42-associated Kinase 1 (Ack1) Is Required for Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor Recruitment to Lipid Rafts and Induction of Cell Death. Journal of Biological Chemistry 2013; 288: 32922-32931.
60. Zhang HB, Zhou XH, McQuade T, Li JH, Chan FKM, Zhang JK. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature 2011; 471: 373-376.
61. Lin Y, Devin A, Cook A, et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of I kappa B kinase and c-Jun N-terminal kinase. Mol Cell Biol 2000; 20: 6638-6645.
62. Elrod HA, Sun SY. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 2008; 7: 163-73.
63. Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 2007; 6: 2591-9.
64. Rossin A, Derouet M, Abdel-Sater F, Hueber AO. Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem J 2009; 419: 185-92, 2 p following 192.
65. Xu L, Qu X, Zhang Y, et al. Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. FEBS Lett 2009; 583: 943-8.
66. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 2004; 21: 461-5.
67. Wagner KW, Punnoose EA, Januario T, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13: 1070-7.
68. Yang ES, Woo SM, Choi KS, Kwon TK. Acrolein sensitizes human renal cancer Caki cells to TRAIL-induced apoptosis via ROS-mediated up-regulation of death receptor-5 (DR5) and down-regulation of Bcl-2. Exp Cell Res 2011; 317: 2592-601.
69. Moon DO, Park SY, Choi YH, Ahn JS, Kim GY. Guggulsterone sensitizes hepatoma cells to TRAIL-induced apoptosis through the induction of CHOP-dependent DR5: Involvement of ROS-dependent ER-stress. Biochem Pharmacol 2011; 82: 1641-50.
70. Lee JC, Chou LC, Huang CH, et al. CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells. Eur J Pharmacol 2011; 670: 96-104.
71. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006; 441: 523-7.
72. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-74.
73. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
74. Nam SY, Jung GA, Hur GC, et al. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 2003; 94: 1066-73.
75. Iyer AK, Azad N, Talbot S, et al. Antioxidant c-FLIP inhibits Fas ligand-induced NF-kappaB activation in a phosphatidylinositol 3-kinase/Akt-dependent manner. J Immunol 2011; 187: 3256-66.
76. Zauli G, Sancilio S, Cataldi A, Sabatini N, Bosco D, Di Pietro R. PI-3K/Akt and NF-kappaB/IkappaBalpha pathways are activated in Jurkat T cells in response to TRAIL treatment. J Cell Physiol 2005; 202: 900-11.
77. Chen X, Thakkar H, Tyan F, et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001; 20: 6073-83.
78. Secchiero P, Gonelli A, Carnevale E, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003; 107: 2250-6.
79. Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005; 280: 15709-18.
80. Song JJ, An JY, Kwon YT, Lee YJ. Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL. J Biol Chem 2007; 282: 319-28.
81. Song JJ, Kim JH, Sun BK, et al. c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment. Cell Signal 2010; 22: 377-85.
82. Lane D, Robert V, Grondin R, Rancourt C, Piche A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer 2007; 121: 1227-37.
83. Peuhu E, Rivero-Muller A, Stykki H, et al. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis. Oncogene 2010; 29: 898-908.
84. Li SS, Yang S, Wang S, Yang XM, Tang QL, Wang SH. Latent membrane protein 1 mediates the resistance of nasopharyngeal carcinoma cells to TRAIL-induced apoptosis by activation of the PI3K/Akt signaling pathway. Oncol Rep 2011; 26: 1573-9.
85. Ding L, Yuan C, Wei F, et al. Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest 2011; 29: 511-20.
86. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001; 276: 10767-74.
87. Asakuma J, Sumitomo M, Asano T, Hayakawa M. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 2003; 63: 1365-70.
88. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86-90.
89. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolu-tionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-60.
90. Jane EP, Premkumar DR, Pollack IF. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol Cancer Ther 2011; 10: 198-208.
91. Kim YS, Schwabe RF, Qian T, Lemasters JJ, Brenner DA. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepa-tology 2002; 36: 1498-508.
92. Kavurma MM, Schoppet M, Bobryshev YV, Khachigian LM, Bennett MR. TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulinlike growth factor-1 receptor. J Biol Chem 2008; 283: 7754-62.
93. Malhi H, Gores GJ. TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 2006; 25: 7333-5.
94. Khanbolooki S, Nawrocki ST, Arumugam T, et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006; 5: 2251-60.
95. Aydin C, Sanlioglu AD, Bisgin A, et al. NF-kappaB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL. BMC Cancer 2010; 10: 584.
96. Morello S, Sorrentino R, Porta A, et al. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells. J Cell Physiol 2009; 221: 378-86.
97. Tanaka H, Hoshikawa Y, Oh-hara T, et al. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation. Mol Cancer Res 2009; 7: 557-69.
98. Omar HA, Arafa el SA, Maghrabi IA, Weng JR. Sensitization of hepatocellular carcinoma cells to Apo2L/TRAIL by a novel Akt/NF-kappaB signalling inhibitor. Basic Clin Pharmacol Toxicol 2014; 114: 464-71.
99. Chen X, Kandasamy K, Srivastava RK. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 2003; 63: 1059-66.
100. Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997; 7: 831-6.
101. Hu WH, Johnson H, Shu HB. Tumor necrosis factor-related apop-tosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 1999; 274: 30603-10.
102. Shin EC, Seong YR, Kim CH, et al. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 2002; 34: 114-22.
103. Zhang B, Shan H, Li D, et al. Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5. Oncol Rep 2011; 25: 461-8.
104. Zhang X, Zhao J, Zhu W, et al. Synergistic Effect of Subtoxic-dose Cisplatin and TRAIL to Mediate Apoptosis by Down-regulating Decoy Receptor 2 and Up-regulating Caspase-8, Caspase-9 and Bax Expression on NCI-H460 and A549 Cells. Iran J Basic Med Sci 2013; 16: 710-8.
105. Lee DH, Kim DW, Lee HC, Lee JH, Lee TH. Phenethyl isothiocy-anate sensitizes glioma cells to TRAIL-induced apoptosis. Biochem Biophys Res Commun 2014; 446: 815-21.
106. Marini P, Schmid A, Jendrossek V, et al. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 2005; 5: 5.
107. Finlay D, Vamos M, Gonzalez-Lopez M, et al. Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs. Mol Cancer Ther 2014; 13: 5-15.
108. Du W, Uslar L, Sevala S, Shah K. Targeting c-Met Receptor Overcomes TRAIL-Resistance in Brain Tumors. PLoS One 2014; 9: e95490.
109. Kauh J, Fan S, Xia M, et al. c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One 2010; 5: e10376.
110. Venza I, Visalli M, Oteri R, Teti D, Venza M. Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP. Int Immunopharma-col 2014; 21: 439-46.
111. Tazzari PL, Tabellini G, Ricci F, et al. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res 2008; 68: 9394-403.
112. Shi J, Zheng D, Man K, Fan ST, Xu R. TRAIL: a potential agent for cancer therapy. Curr Mol Med 2003; 3: 727-36.
113. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 2009; 4: 34-41.
114. Van Geelen CM, Pennarun B, Ek WB, et al. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines. Int J Oncol 2010; 37: 1031-41.
115. Sun SY, Yue P, Zhou JY, et al. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun 2001; 280: 788-97.
116. Charette N, De Saeger C, Horsmans Y, Leclercq I, Starkel P. Sali-rasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms. Cell Death Dis 2013; 4: e471.